Candel Therapeutics' CEO says long-term data bode well for its prostate cancer drug aglatimagene ahead of an FDA submission.
Paul Peter Tak, Candel Therapeutics CEO (via Citryll)
May 15, 2026 11:30 AM EDT
Candel reports prostate cancer drug's long-term data ahead of FDA filing
Candel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that’s heading to the FDA for marketing approval later …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
It’s a crucial moment for the cell and gene therapy field. At the American Society of Gene & Cell Therapy’s annual meeting,…
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally.
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
Biogen's tau-targeting Alzheimer's drug posts mixed results in mid-stage study
Astellas treatment offers new hope to a devastated rare disease community
AstraZeneca scores with Imfinzi in another bladder cancer trial, rivaling Merck's Keytruda
BeOne wins FDA approval in lymphoma race
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
FDA floats possible approach to repurpose approved drugs under new uses
Eisai's slow push toward blockbuster Leqembi sales gains steam with $900M forecast
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
